These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 28434515)
21. [Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer]. Zhang Q; Zhang S Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):66-72. PubMed ID: 28103976 [TBL] [Abstract][Full Text] [Related]
22. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
23. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079 [TBL] [Abstract][Full Text] [Related]
24. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796 [TBL] [Abstract][Full Text] [Related]
25. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803 [TBL] [Abstract][Full Text] [Related]
26. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242 [TBL] [Abstract][Full Text] [Related]
27. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer? Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857 [TBL] [Abstract][Full Text] [Related]
29. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib. Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230 [No Abstract] [Full Text] [Related]
30. Emerging treatment for ALK-positive lung cancer. Sharma J; Pareek V; Liu H; Cheng H Expert Opin Emerg Drugs; 2016 Jun; 21(2):147-55. PubMed ID: 27122312 [TBL] [Abstract][Full Text] [Related]
31. Targeting anaplastic lymphoma kinase in lung cancer. Shaw AT; Solomon B Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922 [TBL] [Abstract][Full Text] [Related]
32. Drug resistance in ALK-positiveNon-small cell lungcancer patients. Qian M; Zhu B; Wang X; Liebman M Semin Cell Dev Biol; 2017 Apr; 64():150-157. PubMed ID: 27693505 [TBL] [Abstract][Full Text] [Related]